CICT Just Spent $3.9 Billion on Paragon.
Here's What Every Unitholder Needs to Know.
If you've been holding CICT (C38U) for a while, you woke up to quite a bombshell on 20 April 2026. Singapore's largest commercial REIT just announced it's buying Paragon — yes, that Paragon on Orchard Road — for a jaw-dropping S$3.9 billion, while simultaneously offloading Asia Square Tower 2 (AST2) for S$2.476 billion.
Two mega-transactions, announced on the same day. Bold move, CICT. Bold move.
As someone who follows S-REITs closely, I dug into the numbers so you don't have to sieve through 50 pages of SGX announcements. Let me break it all down — what happened, how they're paying for it, and whether this is actually good news for us unitholders.
- CICT buys Paragon (freehold, Orchard Rd) for S$3.9B, sells AST2 (leasehold, Marina Bay) for S$2.476B
- Funding: AST2 proceeds + S$750M private placement + remaining debt
- DPU accretion: +2.1% on a pro forma basis (11.58¢ → 11.83¢)
- Leverage stays comfortable at 39.2% post-deal (vs 50% limit)
- Existing unitholders get an advanced distribution of ~3.93–4.03¢ per unit
- EGM needed — completion expected Q3 2026
First — What Exactly Is Paragon?
Unless you've been living under a rock, Paragon at 290 Orchard Road is one of Singapore's most iconic luxury retail and medical properties. We're talking about a six-storey upscale mall, two basement levels, plus two office and medical towers (one of which is 14 storeys tall).
The tenant mix is premium: over 190 retail and lifestyle brands (think luxury fashion, premium F&B) alongside more than 80 multidisciplinary medical clinics. This isn't your neighbourhood Lot One. This is Orchard Road's crème de la crème.
And here's the kicker that makes this deal special: Paragon is freehold.
In land-scarce Singapore, freehold commercial properties in prime Orchard Road are rarer than a hawker stall with no queue. Unlike AST2 which had 81 years left on its leasehold, Paragon will never expire. That's a structural quality upgrade for CICT's portfolio right there.
"Paragon is a rare, premier freehold integrated development… combining sizeable, upscale retail exposure with a defensive medical component."
As at January 2026, committed occupancy was 100% for both the retail and medical/office components. Not 95%. Not 97%. One hundred percent. That's not easy to achieve for any mall, let alone in the current environment.
The Simultaneous Sale: Bye Bye, Asia Square Tower 2
CICT isn't just buying Paragon blind — they're funding part of it by selling Asia Square Tower 2 to IOI Marina View Pte. Ltd. (a unit of Malaysian developer IOI Properties) for S$2.476 billion.
That's a 9.9% premium over AST2's December 2025 valuation of S$2.252 billion. Smart timing by the managers — they waited for AST2 to mature and are cashing out near the top.
The exit yield on AST2 is 3.0%. The entry yield on Paragon? 3.9%. You don't need a finance degree to see that CICT is selling lower-yielding leasehold exposure and recycling it into higher-yielding freehold. The yield spread alone is a 90 basis point improvement.
| Metric | AST2 (Selling) | Paragon (Buying) |
|---|---|---|
| Price | S$2.476B | S$3.9B |
| Tenure | Leasehold (81 yrs left) | Freehold ✓ |
| Asset Type | Office | Retail + Medical + Office |
| Net Yield | 3.0% | 3.9% |
| Occupancy | Stable (reaching plateau) | 100% committed |
| vs Valuation | +9.9% premium ✓ | Broadly in line |
The sale of AST2 is subject to the buyer's own shareholder approval and an IRAS tax confirmation, with completion expected in H2 2026. Since the timelines don't perfectly overlap, CICT is using a bridging loan to cover the gap if Paragon closes before AST2 proceeds land. Standard stuff for large M&A transactions.
How Is CICT Funding The $3.9 Billion?
Right, let's talk money. The total acquisition outlay (including transaction costs) is about S$3.919 billion. After netting off AST2's proceeds of approximately S$2.45 billion, CICT still needs to find about S$1.47 billion from somewhere.
Here's the funding breakdown:
1. Private Placement — S$750 Million
CICT launched a private placement targeting at least S$600 million in fresh equity. The response from institutional and accredited investors was — honestly — overwhelming. The book was 4.8 times covered and was upsized to S$750 million.
The issue price was fixed at S$2.30 per new unit, a ~4.0% discount to the volume-weighted average price of S$2.3955 on 17 April 2026. A total of 326,087,000 new units will be issued, representing about 4.28% of total units outstanding. New units start trading on SGX on 29 April 2026.
Yes, 326 million new units is a lot. But at 4.28% dilution, it's relatively modest for a deal of this size. The managers priced it near the midpoint of the range — not at the top — which shows institutional investors still pushed for a meaningful concession. Fair enough.
To protect existing unitholders, CICT will declare an advanced distribution of ~3.93 to 4.03 cents per unit for income accrued from 1 January 2026 up to the day before the new units are issued. New unit buyers from the placement do NOT get this. So if you're an existing holder, you're getting a fairness payment first — which is the right move.
2. AST2 Divestment Proceeds — ~S$2.45 Billion
The lion's share of funding. Estimated net proceeds after adjustments come to approximately S$2.45 billion, which directly offsets the bulk of Paragon's cost. If AST2 completes before Paragon (which is uncertain given the buyer needs their own EGM approval), great. If not, CICT uses a bridging loan in the interim.
3. Remaining Debt
The balance (~S$720 million or so) will be taken on as debt. Post-transaction, pro forma aggregate leverage is expected to land at 39.2% — well within the 50% regulatory cap and leaving ample room for future acquisitions.
DPU Impact: The Part You Actually Care About
On a pro forma basis, if both transactions had been completed on 1 January 2025, FY2025 DPU would have risen from 11.58¢ to 11.83¢ — a 2.1% uplift.
2.1% may not sound like a lot, but think about it: this is after absorbing the dilution from 326 million new units, funding cost from additional debt, and the loss of AST2's income. That the net result is still accretive is genuinely encouraging. The Paragon yield (3.9%) doing real work here.
Beyond the base DPU accretion, there's a potential kicker: CICT is evaluating a major Asset Enhancement Initiative (AEI) for Paragon with capex estimated at S$300 million or more. If that goes ahead, there's room for further rental upside down the road. But that's speculative for now — let's not get ahead of ourselves.
The Structural Tailwinds Angle
I want to spend a moment on why Paragon's medical component is actually underrated. Singapore's population is ageing fast. Medical tourism is growing. And unlike retail — which can be disrupted by e-commerce — medical clinics don't go online. You can't see a specialist via Shopee.
The 80+ multidisciplinary clinics in Paragon's towers provide a sticky, defensive income stream that insulates CICT from pure retail cyclicality. This isn't just a luxury mall play — it's a hybrid with a resilient anchor.
On the retail side, Orchard Road's supply pipeline is tight. Not much new retail space coming onto the belt in the next few years. And Orchard Road rents have been grinding upward at about 3% annually since 2021. Paragon, with its 100% occupancy and premium positioning, is well-placed to capture that rental growth.
Risks to Watch
I'd be doing you a disservice if I only gave you the bull case. Here are the things I'm keeping my eyes on:
1. EGM approval risk. Because Paragon's vendors (Cuscaden Peak, a 50:50 JV between CapitaLand Investment and Temasek's Mapletree) are related to CICT's sponsor, this counts as an interested person transaction. Unitholders need to vote yes at an EGM expected in Q2 or Q3 2026. The deal doesn't close without us. Given the deal's quality, I expect approval — but it's not a rubber stamp until it happens.
2. Bridging loan timing risk. If Paragon acquisition closes before AST2's sale completes, CICT takes on more debt temporarily. Interest rates still matter, and this gap could drag near-term distributions slightly.
3. AEI execution risk. A S$300 million-plus AEI is ambitious. If it happens, there will be some tenant disruption and capital commitment. Needs watching.
4. Valuation premium paid. At S$5,455 PSF, CICT is paying a full price for Paragon. But given it's freehold, Orchard Road, 100% occupied — the market is pricing in scarcity. You don't get deals on irreplaceable assets.
This Deal Is a Quality Upgrade for CICT
Honestly? I like this deal. Selling a maturing, leasehold office asset at a premium — and recycling that into a freehold, 100%-occupied, multi-income-stream trophy property on Orchard Road — is textbook good REIT management.
The 2.1% DPU accretion is real (not just pro forma fluff). Leverage remains disciplined. The advanced distribution protects existing unitholders from placement dilution. And Paragon's freehold status means the asset value doesn't erode over time the way leasehold does.
Is S$2.30 a good entry price for the placement participants? At a ~4.8% forward yield, probably — if you can get access (it's institutional-only). For the rest of us retail unitholders, the key question is: do you vote yes at the EGM and hold for the DPU uplift? I'd say yes.
CICT is already Singapore's largest commercial REIT. After this deal, it becomes an even harder-to-replicate portfolio. That's not nothing.
Key Dates to Mark
| Date | Event |
|---|---|
| 20 April 2026 | Announcement of Paragon acquisition + AST2 divestment + private placement launch |
| 22 April 2026 | CICT AGM — general mandate for unit issuance expected |
| 28 April 2026, 5pm | Record date for advanced distribution (~3.93–4.03¢ per unit) |
| 29 April 2026 | New placement units commence trading on SGX |
| Q2–Q3 2026 | EGM for unitholder approval of Paragon acquisition |
| Q3 2026 (expected) | Completion of Paragon acquisition |
| H2 2026 (expected) | Completion of AST2 divestment |
Bottom line: the EGM is the one to watch. That's where unitholders like you and me decide if this deal happens. Based on everything I've read, I'd be voting yes — and I suspect most institutional holders will too.
What do you think of this deal? Are you a CICT unitholder? Drop a comment below — I'd love to hear how fellow S-REIT investors are reading this one.
Thanks for reading.
With love & peace, Qiongster. 🙏
No comments:
Post a Comment